Q: Hello team,
What is wrong with FDA wanting to review CorMedix's "full data set including secondary endpoints from the LOCK-IT-100 study to facilitate FDA's consideration of CorMedix's request to file the New Drug Application (NDA) for Neutrolin on the basis of the LOCK-IT-100 study results."
Why the 27% drop after the meeting with FDA and willingness of the company to provide the data and fully cooperate?
Hold, Sell, or Average down on CRMD?
Thanks as always.
What is wrong with FDA wanting to review CorMedix's "full data set including secondary endpoints from the LOCK-IT-100 study to facilitate FDA's consideration of CorMedix's request to file the New Drug Application (NDA) for Neutrolin on the basis of the LOCK-IT-100 study results."
Why the 27% drop after the meeting with FDA and willingness of the company to provide the data and fully cooperate?
Hold, Sell, or Average down on CRMD?
Thanks as always.